The recurring failure to translate neuroprotective strategies in animal models into clinical settings prompted us to reevaluate existing preclinical stroke models.
Despite a well-documented role of CD36 in the pathogenesis of conditions such as atherosclerosis, inflammation and lipid metabolism, its role in cerebral ischemic injury had not been recognized at the time I initiated the st
